Dr. Singh has led groundbreaking studies in anemia of kidney disease, including the CHOIR study, which was published in the New England Journal of Medicine, and well as being a member of the steering committees for the TREAT and DRIVE studies. More recently, he has taken on the role of leading the ASCEND Clinical development program - a phase 3 program for the development of a novel propyl hydroxylase inhibitor Daprodustat. The trial is aiming to recruit 7500 patients in over countries. He currently leads the office of Postgraduate Medical Education at the Brigham and Women's Hospital, and in this capacity leads several HMS CME courses. He is the author of over 160 original contributions and review articles, as well as author/editor of 11 books in internal medicine and nephrology. Dr. Singh is a Fellow of the Royal College of Physicians in London, and has an MBA from Boston University.